Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

Area of Science:

• Endocrinology
• Diabetes Mellitus Management
• Pharmacovigilance

Background:

• Hypoglycaemia is a significant adverse event associated with diabetes therapies, particularly insulin.
• The burden of hypoglycaemia impacts patients and healthcare systems, necessitating careful risk-benefit assessments for new basal insulins (BIs).
• Regulatory approval for BIs often requires demonstrating a balance between glycemic control and reduced hypoglycaemia risk.

Purpose of the Study:

• To review and analyze the discrepancies in hypoglycaemia reporting across randomized controlled trials (RCTs) and real-world evidence (RWE) studies of second-generation BI analogues.
• To identify potential reasons for these reporting differences.
• To highlight the need for standardized reporting methods to facilitate accurate comparisons of BI safety and efficacy.

Main Methods:

• The review synthesizes data from published RCTs and RWE studies focusing on second-generation basal insulin analogues.
• It critically examines methodologies for defining, measuring, and reporting hypoglycaemic events in these diverse study designs.
• The analysis identifies variations in study duration, glycemic targets, hypoglycaemia definitions, and assessment intervals for nocturnal events.

Main Results:

• Substantial heterogeneity exists in the reporting of hypoglycaemia across RCTs and RWE studies involving BIs.
• These differences confound direct comparisons of hypoglycaemia incidence and severity between different BI therapies.
• Even newer second-generation BI analogues, while offering improved safety profiles, do not eliminate the risk of hypoglycaemia.

Conclusions:

• Standardization of study design, analysis, and reporting methods for hypoglycaemia in BI trials is urgently needed.
• Consistent definitions and reporting intervals are essential for accurate interpretation of BI efficacy and safety data.
• Improved standardization will enable better clinical decision-making and patient care in diabetes management.